- Tekturna HCT combines first approved direct renin inhibitor with the
diuretic hydrochlorothiazide (HCTZ) in a single tablet
- Data show combination of Tekturna and HCTZ resulted in significant
additional blood pressure reductions compared to either drug alone
- Many treated patients are not at goal and most require two or more medicines - single-tablet combinations simplify treatment by reducing
number of pills patients take
EAST HANOVER, N.J., Jan. 21 /PRNewswire/ -- Tekturna HCT(R) (aliskiren
and hydrochlorothiazide) tablets has been approved by the US Food and Drug
Administration as a single-tablet combination of two high blood pressure
medicines -- Tekturna(R) (aliskiren), the first approved direct renin
inhibitor, and the diuretic hydrochlorothiazide (HCTZ).
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/novartis/31084/
The two medicines in this single-tablet combination work together to lower blood pressure, with clinical data showing that the combination of Tekturna and HCTZ offers greater blood pressure reductions than either component alone.
This is the first regulatory approval of a single-tablet combination therapy involving Tekturna, known as Rasilez(R) outside the US. HCT, sometimes called a "water pill", is one of the most commonly-used high blood pressure medicines. Tekturna HCT is approved for patients not controlled by either medicine alone but should not be used before other medications have been tried first.
"Current guidelines call for aggressive treatment of high blood
pressure because approximately 40% of treated patients are still not
controlled," said Alan Gradman, MD, Division of Cardiovascular Diseases at
the Western Pennsylvania Hospital in Pittsburgh, PA. "Tekturna HCT offers
patients an effective new treatment option with signific
Copyright©2008 PR Newswire.
All rights reserved